Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.25% | 20.47% | 11.24% | -23.14% | -0.10% |
| Total Depreciation and Amortization | -25.81% | -23.46% | 9.46% | -7.50% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.41% | -11.67% | 15.28% | 6.74% | 8.69% |
| Change in Net Operating Assets | 876.43% | -150.16% | 112.54% | -389.41% | -110.22% |
| Cash from Operations | -19.27% | 22.15% | 29.30% | -40.25% | -41.09% |
| Capital Expenditure | -100.00% | 100.72% | -595.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 399.73% | 97.79% | -12,777.95% | 99.04% | -95.10% |
| Cash from Investing | 405.05% | 97.79% | -12,965.38% | 96.29% | -95.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 93,223.93% | -99.41% | 3,478.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.65% | -- | -- | -- | -- |
| Cash from Financing | 269.29% | -100.17% | 93,223.93% | -99.41% | 3,478.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.98% | -199.85% | 178.93% | -195.62% | 526.56% |